Laëtitia Dahan
机构：Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Institut de Neurosciences de la Timone, Hôpital de la Timone · ORCID：0000-0001-5267-6190
发表论文 245 篇 · 总被引 9837 次 · h-index 46
代表论文
- Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer (2024 · New England Journal of Medicine · 被引 267)
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial (2025 · The Lancet · 被引 224)
- Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial (2025 · The Lancet · 被引 39)
- Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study) (2025 · Journal of Clinical Oncology · 被引 26)
- FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2024 · JAMA Oncology · 被引 14)
- LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo) (2024 · Annals of Oncology · 被引 12)